‘Chemo mouth’, otherwise known as oral mucositis, has emerged as the most significant adverse event in oncology, according to a National Comprehensive Cancer Network task force.
Eli Lilly may be on the brink of reshaping the pharma landscape, with its treatments, Mounjaro (tirzepatide) for obesity and the highly anticipated donanemab for early symptomatic Alzheimer’s disease.
During DCAT this year, CEO Gaston Salinas from Botanical Solution Inc., (BSI), sat down with Liza Laws, the senior editor of OSP and BPR to discuss his company’s pioneering work in revolutionizing vaccine adjuvant production.
Pfizer’s drug Velsipity (etrasimod), for the treatment of moderate to severe ulcerative colitis (UC), recently received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
In the fast-paced domain of pharmaceutical contract development and manufacturing organizations (CDMOs), Selkirk Pharma believes it stands out as a beacon of innovation and reliability.
Specific doses of Eli Lilly’s GLP-1 blockbuster drugs Mounjaro and Zepbound are currently facing a supply shortage, and frustrated patients are urging the pharma giant to act – fast.
Bio Pharma Reporter and Outsourcing Pharma is back with our latest instalment of movers and shakers - breaking down all the key pharma industry appointments that you should know about. KBI Biopharma, Veranova and Kindeva Drug Delivery are among the companies...
Recurring urinary tract infections (UTIs) can be prevented for up to nine years with a simple oral spray vaccine, a ‘breakthrough’ British trial has shown.
Last week (April 5), the American Association for Cancer Research (AACR) welcomed the industry to the San Diego Convention Center for the AACR Annual Meeting 2024.
Pharma giant Novo Nordisk is firing back after Senator Bernie Sanders took a stand against the ‘outrageous’ prices of its wildly popular drugs, Ozempic and Wegovy.
Today, just two in ten patients have access to CAR-T therapy in the US. Considering this challenging landscape, the shift has focused from academic centers to community clinics, as they may be able to serve more patients.
Ipsen is expanding its oncology pipeline by securing the global licensing rights to an antibody-drug conjugate (ADC) for solid tumors from Sutro Biopharma, its first drug in the category.
Consumer health company Haleon has published a first-of-its kind study highlighting the significant positive impact that its nasal decongestant Otrivin can have on patients’ quality of life.
“When you have people who like what they do and believe they’re having an impact, you can do anything – more than any project or investment. Prioritise your teams and people because they’re your biggest asset.”
Curve Therapeutics, a biotech pioneering an intracellular screening platform addressing complex and challenging disease targets, has announced the publication of an article in the Journal of the American Chemical Society (JACS).
This week, the pharma industry will descend on Pennsylvania Convention Center for Reuters Pharma USA, North America’s largest cross-functional pharma gathering.
The recent submission of clinical trial data for Sanofi/Regeneron’s Dupixent and Verona’s Ensifentrine to the U.S. FDA indicates the entry of new therapies for chronic obstructive pulmonary disease (COPD) in 2024.
Dr. Claudia Zylberberg is a scientist and founder, board member and former CEO of Akron Biotech, a company that makes materials and technologies to support advanced therapy development. We spoke to her about her career, personal triumphs and candidacy...
AstraZeneca recently announced its £650 million investment in the UK, held up by Chancellor Jeremy Hunt as a ‘vote of confidence’ in the country’s life sciences sector.
Since Roche's Zelboraf (vemurafenib)gained FDA approval in 2011, significant strides have been made in BRAF-targeted cancer therapies, underscoring the significance of combating BRAF mutations in melanoma.
Within the current treatments of Parkinson’s disease (PD) there is an unmet need for addressing the loss of dopaminergic neurons and non-motor symptoms.
The U.S. Food and Drug Administration has cleared AGC Biologics’ Milan site to begin manufacturing of Orchard Therapeutics’ Lenmeldy (atidarsagene autotemcel), a gene therapy for early-onset metachromatic leukodystrophy (MLD).
Eli Lilly is partnering with ecommerce titan Amazon to deliver its weight loss drug Zepbound straight to patient’s doors, in a bid to address ongoing shortages.
Biopharma company Clene has published ‘impactful’ new research into CNM-Au8, its investigational drug in development for the treatment of neurodegenerative diseases.
ReciBioPharm has partnered with pre-clinical gene therapy company GeneVentiv Therapeutics to advance development of an Adeno-Associated Virus (AAV)-based universal gene therapy for haemophilia, and the first to treat haemophilia patients with inhibitors.
With a treatment for hypoparathyroidism in late-stage development and other promising drugs in Amolyt's pipeline, the $1.05 billion deal is the latest in big pharma's push into rare disease research
Kate Broderick takes us on her intriguing journey - from being drawn to how science was applied within a medical setting, to the enormous challenge of working around the clock when the pandemic began.
The unprecedented demand for GLP-1 medicines, fuelled by their remarkable ability to help patients shed up to 20% of body weight, has been nothing short of explosive.
Bristol Myers Squibb’s Opdivo was recently granted FDA approval in combination with cisplatin and gemcitabine as a first-line treatment for metastatic urothelial carcinoma (mUC).
One of the most challenging aspects of the COVID-19 pandemic was not being able to assess how individual patients would respond to the virus and how severe their symptoms would be.
Despite previously calling the UK a ‘very unattractive’ place to do business, AstraZeneca CEO Pascal Soriot is injecting £650 million into the UK life sciences industry.
Swedish-based company Empros Pharma has announced positive topline data from its phase 2b trial investigating EMP16, an oral therapy for the treatment of obesity.
Biotech company Transgene, IT solutions provider NEC, and biomedical software company BostonGene have expanded their collaboration for the phase 1/2 trial of TG4050, an individualized therapeutic vaccine for patients with head and neck cancers.
Hayley Crowe is executive vice president and general manager of Ecolab’s Global Life Sciences sector, comprised of Ecolab’s Purolite and pharma / personal care businesses. We sat down with Hayley to discuss how adversity inspired her determination to...
Terumo Blood and Cell Technologies is working to improve treatment for pregnant sickle cell sufferers, publishing first-of-its-kind international consensus recommendations for these patients.
Neurogene, a clinical-stage company developing genetic medicines, is expanding its ongoing phase 1/2 clinical trial investigating NGN-401 as a treatment for female pediatric patients with Rett Syndrome.
SolasCure is moving forward with its maggot-derived wound gel, after publishing the results of its recent phase 2 clinical trial in a leading wound care journal.
California-based biotech company Metabolomycs has released a new study demonstrating how pancreatic cancer could be diagnosed earlier with a blood test.
Biogen’s stance at the upcoming AD/PD 2024 International Conference on Alzheimer’s disease and Parkinson’s disease will demonstrate its future plans for treating Alzheimer’s, following the discontinuation of Aduhelm (aducanumab), its anti-amyloid beta...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently refused marketing authorization for Nezglyal (leriglitazone).